CEFOXITIN FOR INJECTION USP 1 G
CEFOXITIN (CEFOXITIN SODIUM) : 1 G · DIN 02291711 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is CEFOXITIN FOR INJECTION USP?
CEFOXITIN FOR INJECTION USP 1 G contains CEFOXITIN (CEFOXITIN SODIUM) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02291711, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 28-Jun-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFOXITIN FOR INJECTION USP used for?
Treatment of intra-abdominal, gynecological, septicemia, urinary tract, lower respiratory, bone/joint, and soft tissue infections. Perioperative prophylaxis for abdominal and vaginal surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02291711 |
|---|---|
| Brand name | CEFOXITIN FOR INJECTION USP |
| Generic / active ingredient | CEFOXITIN (CEFOXITIN SODIUM) : 1 G |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 1 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01DC01 CEFOXITIN |
| AHFS class | 08:12.07.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Jun-2019 |
| Original market date | 2007-12-21 00:00:00 |
How is it administered?
Adults: 1-2 g every 6-8 hours (IV or IM). Max 12 g/day. Prophylaxis: 2 g prior to surgery, then 2 g at 2-6 hour intervals for 12-24 hours. Adjust dose for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at a controlled temperature between 15°C and 25°C. Protect from light. Reconstituted solutions stable for 8h at room temp or 72h refrigerated.
How is it supplied?
Supplied in vials containing 1 g or 2 g of cefoxitin as the sodium salt.
Contraindications
Hypersensitivity to cefoxitin or other cephalosporin antibiotics. Not recommended for the treatment of meningitis.
Warnings and precautions
Risk of cross-allergenicity with penicillins. Serious hypersensitivity/anaphylaxis possible. Pseudomembranous colitis reported. Risk of overgrowth of non-susceptible organisms.
Is CEFOXITIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DC01 CEFOXITIN. 2 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFOXITIN FOR INJECTION | 1 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02128187 |
| CEFOXITIN FOR INJECTION | 2 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02128195 |
| CEFOXITIN FOR INJECTION | 10 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02240773 |
| CEFOXITIN FOR INJECTION USP | 2 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02291738 |
| MEFOXIN INJ 1GM/VIAL ADD-VANTAG | 1 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00893668 |
| MEFOXIN INJ 2GM/VIAL ADD-VANTAG | 2 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00893676 |
| MEFOXIN PWS 1GM/VIAL | 1 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00663697 |
| MEFOXIN PWS 2GM/VIAL | 2 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00663700 |
| MEFOXIN PWS INJ 10GM/VIAL | 10 G | POWDER FOR SOLUTION | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 01980653 |
Who else supplies CEFOXITIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFOXITIN appears in 7 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.